Study of the action of tamoxifen on the mammary gland epithelium of premenopausal patients by lysosome quantification
Abstract
Tamoxifen is an antiestrogen drug widely utilized for the adjuvant hormonal treatment of breast carcinoma. Its use in the primary prophylaxis of this disease is currently being proposed. Although the drug has few side effects, its precise action on breast tissue that has not undergone neoplastic transformation has not been fully elucidated. This prospective, randomized study assessed the estrogen activity of tamoxifen on the mammary gland epithelium of premenopausal patients using a quantitative analysis of mammary epithelium lysosomes identified by the cytochemical technique of GOMORI for acid phosphatase and by light microscopy. Tamoxifen significantly increased the number of lysosomes only during the secretory phase of the menstrual cycle. We concluded that the early effect of the drug on normal mammary tissue is synergistic with the effect of estrogen during the premenopausal period.
Downloads
References
Jordan VC. Target hormone therapy for breast cancer. Hospital Practice 1993;15:55-62.
Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985;ii:282.
Fornander T, Rutqvist LE, Cedermark et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989;i:117-20.
Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1988;57:608-11.
Powles TJ, Davey J, McKinna A. Chemoprevention of breast cancer. Acta Oncol 1990;28:865-7.
De Duve C, Berthet J, Hers HG, Dupret L. Le système hexose-phosphatase specifique dans le foie. Bull Soc Chim Biol 1949;31:1242-53.
Podhajcer OL, Filmus JE, Mordoh J. Characterization of lysosomal acid phosphatase from normal and malignant mammary tissue. Clin Chem 1986;32:279-82.
Talukdar C, Ghosh S. Peroxidase activities in human breast tumours in relation to menstrual status of the patients. Indian J Res 1984:79:801-5
Girão MJBC, Baracat EC, Lima GR, Simões MJ. Variacions cuantitativas de los lisosomas en el epitelio alveolar de la glandula mamaria humana en las fases proliferative y secretora do ciclo menstrual. Rev Chil Obstet Ginecol 1.991;56(2):107-10.
Gomori G. Microscopic histochemistry: Principles and practice. Chicago: University Chicago Press, 1952:137-221.
Pricoli TI. Estudo comparativo dos lisossomos do hepatócito nas formas hepato-intestinal e hepato-esplênica da esquistossomose mansônica humana. Tese de Doutoramento, Escola Paulista de Medicina. São Paulo 1972:78.
Martins NV. Variações quantitativas dos lisossomos no epitélio endometrial de ratas na fase de estro, ooforectomizadas e ooforectomizadas tratadas com estrogênio. São Paulo, 1983:50. [Tese Doutorado - Escola Paulista de Medicina]
Siegel S. Estadistica no paramétrica aplicada a las ciencias de la conducta. 2ª reimp. Mexico: Trillas, 1975:143-55.
Costa A, Love RR. Breast cancer prevention with tamoxifen: The Madison meetings. Eur J Cancer 1990;26:656-7.
Fentiman IS. The role of tamoxifen in the prevention of breast cancer. Eur J Cancer 1990;26:655-6.
Fentiman IS, Owles TJ. Tamoxifen and benign breast problems. Lancet 1987;ii:1070-1.
Bond JP, Sasson S, Notides AC. The binding of estrogen and estrogen antagonists to the estrogen receptor. Arch Biochem Biophys 1992;296:583-91.
Leis HP. The role of tamoxifen in prevention and treatment of benign and malignant breast lesions: A chemopreventive. Int Surg 1993;78:176-82.
Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer 1993;71:1266-72.
Zamith R, Baracat EC, Rodrigues De Lima G, Gebrim LH, Simões MJ. Quantitative study of the lysosomes of epithelial cells from human mammary glands and fibroadenoma during proliferative and secretory phase of the menstrual cycle. Bull Assoc Anat 1994;78:19-21.
Sutherland MC, Osborne CK. Tamoxifen in the premenopausal patients with metastatic breast cancer: A review. J Clin Oncol 1991;9:1283-97.
Nazário ACP, Rodrigues De Lima G, Simões MJ, Novo NF. Cell kinetics of the human mammary lobule during the proliferative and secretory phase of the menstrual cycle. Bull Assoc Anat 1995;79(244):23-7.
Pham TA, Elliston JF, Nawaz Z, Mxdonnell DP, Tsa MJ, O'Malley BW. Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. Proc Natl Acad Sci 1991;88:3125-9.
Tzukerman MT, Esty A, Santiso-Mere D, et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994;8:21-30.
